Etifoxine Versus Alprazolam for the Treatment of Adjustment Disorder with Anxiety: a Randomized Controlled Trial

Advances in Therapy

Volumn 32, Issue 1, 2015, Pages 57-68

  Stein, Dan J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Adjustment disorder with anxiety; Alprazolam; Etifoxine

Indexed keywords

ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BENZOXAZINE DERIVATIVE; ETIFOXINE; UNCLASSIFIED DRUG; OXAZINE DERIVATIVE;

ADJUSTMENT DISORDER; ADJUSTMENT DISORDER WITH ANXIETY; ADULT; ANXIETY DISORDER; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONOTHERAPY; CLINICAL GLOBAL IMPRESSION SCALE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EFFICACY; DRUG OVERDOSE; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAMILTON ANXIETY SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; OUTPATIENT; PARALLEL DESIGN; PATIENT COMPLIANCE; PREDICTOR VARIABLE; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SEDATION; SELF REPORT; SHEEHAN DISABILITY SCALE; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ADJUSTMENT DISORDERS; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; PSYCHOLOGICAL ADJUSTMENT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SOCIAL ADAPTATION;

ADJUSTMENT DISORDERS; ADULT; ALPRAZOLAM; ANTI-ANXIETY AGENTS; DOUBLE-BLIND METHOD; EMOTIONAL ADJUSTMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZINES; PSYCHIATRIC STATUS RATING SCALES; SOCIAL ADJUSTMENT; TREATMENT OUTCOME;

EID: 84925465508     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0176-6     Document Type: Article

References (32)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Publishing; 1980.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorder. 5th ed. Arlington: American Psychiatric Publishing; 2013.
3. Casey P. Adjustment disorder: new developments. Curr Psychiatry Rep. 2014;16(6):451.
4. Jäger M, Frash K, Becker T. Adjustment disorders—nosological state and treatment options. Psychiatr Prax. 2008;35:219–25.
5. Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry. 2005;162:1171–8.
6. Carta MG, Balestrieri M, Murru A, Hardoy MC. Adjustment disorder: epidemiology, diagnosis and treatment. Clin Pract Epidemiol Ment Health. 2009;5:15.
7. Arends I, Bruinvels DJ, Rebergen DS, Nieuwenhuijsen K, Madan I, Neumeyer-Gromen A, Bültmann U, Verbeek JH. Interventions to facilitate return to work in adults with adjustment disorders. Cochrane Database Syst Rev. 2012;12.
8. Esposito E, Barbui C, Patten SB. Patterns of benzodiazepine use in a Canadian population sample. Epidemiol Psichiatr Soc. 2009;18:248–54.
9. Baldwin DS, Aitchison K, Bateson A, Curran HV, Davies S, Leonard B, Nutt DJ, Stephens DN, Wilson S. Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol. 2013;27(11):967–71.
10. Verleye M, Schlichter R, Gillardin JM. Interactions of etifoxine with the chloride channel coupled to the GABAA receptor complex. NeuroReport. 1999;10:3207–10.
11. Schlichter R, Rybalchenko V, Poisbeau P, Verleye M, Gillardin JM. Modulation of GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine. Neuropharmacology. 2000;39:1523–35.
12. Verleye M, Pansart Y, Gillardin JM. Effects of etifoxine on ligand binding to GABAA receptors in rodents. Neurosci Res. 2002;44:167–72.
13. Hamon A, Morel A, Hue B, Verleye M, Gillardin JM. The modulatory effects of the anxiolytic etifoxine on GABAA receptors are mediated by the β subunit. Neuropharmacology. 2003;45:293–303.
14. Verleye M, Akwa Y, Liere P, Ladurelle N, Pianos A, Eychenne B, Schumacher M, Gillardin JM. The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol Biochem Behav. 2005;82:712–20.
15. Ugale RR, Sharma AN, Kokare DM, Kokare DM, Hirani K, Subhedar NK, Chopde CT. Neurosteroid allopregnanolone mediates anxiolytic effect of etifoxine in rats. Brain Res. 2007;1184:193–201.
16. Servant D, Graziani PL, Moyse D, Parquet PJ. Treatment of adjustment with anxiety: efficacy and safety of etifoxine in a double-blind controlled study. Encephale. 1998;24:569–74.
17. Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, Blin O. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol. 2006;21:139–49.
18. Micallef J, Soubrouillard C, Guet F, Le Guern ME, Alquier C, Bruguerolle B, Blin O. A double blind parallel group placebo controlled comparison of sedative and amnesic effects of etifoxine and lorazepam in healthy subjects. Fundam Clin Pharmacol. 2001;15:209–16.
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Publishing; 1994.
20. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–5.
21. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(Suppl 3):89–95.
22. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.
23. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33.
24. Guy W. Clinical Global Impression Scale (CGI). ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health-US Dept of Health, Education, and Welfare publication (ADM); 1976, pp. 76–338.
25. Maercker A, Einsle F, Köllner V. Adjustment disorders as stress response syndromes: a new diagnostic concept and its exploration in a medical sample. Psychopathology. 2007;40:135–46.
26. Einsle F, Köllner V, Dannemann S, Maercker A. Development and validation of a self-report for the assessment of adjustment disorders. Psychol Health Med. 2010;15:584–95.
27. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44(2):77–87.
28. Rickels K, Schweizer E, DeMartinis N, Mandos L, Mercer C. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol. 1997;17:272–7.
29. Cohn JB, Wilcox CS. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study. J Clin Psychiatry. 1986;47(986):409–12.
30. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50:884–95.
31. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA. 2000;283(23):3082–8.
32. De Leo D. Treatment of adjustment disorders: a comparative evaluation. Psychol Rep. 1989;64(1):51–4.